252 related articles for article (PubMed ID: 23368980)
1. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough.
Oxberry SG; Bland JM; Clark AL; Cleland JG; Johnson MJ
J Palliat Med; 2013 Mar; 16(3):250-5. PubMed ID: 23368980
[TBL] [Abstract][Full Text] [Related]
2. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial.
Oxberry SG; Torgerson DJ; Bland JM; Clark AL; Cleland JG; Johnson MJ
Eur J Heart Fail; 2011 Sep; 13(9):1006-12. PubMed ID: 21712288
[TBL] [Abstract][Full Text] [Related]
3. Minimally clinically important difference in chronic breathlessness: every little helps.
Oxberry SG; Bland JM; Clark AL; Cleland JG; Johnson MJ
Am Heart J; 2012 Aug; 164(2):229-35. PubMed ID: 22877809
[TBL] [Abstract][Full Text] [Related]
4. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study.
Johnson MJ; McDonagh TA; Harkness A; McKay SE; Dargie HJ
Eur J Heart Fail; 2002 Dec; 4(6):753-6. PubMed ID: 12453546
[TBL] [Abstract][Full Text] [Related]
5. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam.
Allcroft P; Margitanovic V; Greene A; Agar MR; Clark K; Abernethy AP; Currow DC
J Palliat Med; 2013 Jul; 16(7):741-4. PubMed ID: 23597092
[TBL] [Abstract][Full Text] [Related]
6. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?
Currow DC; Quinn S; Ekstrom M; Kaasa S; Johnson MJ; Somogyi AA; Klepstad P
BMJ Open; 2015 May; 5(5):e006818. PubMed ID: 25948405
[TBL] [Abstract][Full Text] [Related]
7. Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness--An Exploratory Study.
Ferreira DH; Silva JP; Quinn S; Abernethy AP; Johnson MJ; Oxberry SG; Currow DC
J Pain Symptom Manage; 2016 Feb; 51(2):247-54. PubMed ID: 26598037
[TBL] [Abstract][Full Text] [Related]
8. Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).
van Dijk M; Mooren KJM; van den Berg JK; van Beurden-Moeskops WJC; Heller-Baan R; de Hosson SM; Lam-Wong WY; Peters L; Pool K; Kerstjens HAM
BMC Pulm Med; 2021 Sep; 21(1):289. PubMed ID: 34507574
[TBL] [Abstract][Full Text] [Related]
9. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial.
Currow D; Louw S; McCloud P; Fazekas B; Plummer J; McDonald CF; Agar M; Clark K; McCaffrey N; Ekström MP;
Thorax; 2020 Jan; 75(1):50-56. PubMed ID: 31558624
[TBL] [Abstract][Full Text] [Related]
10. Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial.
Johnson MJ; Cockayne S; Currow DC; Bell K; Hicks K; Fairhurst C; Gabe R; Torgerson D; Jefferson L; Oxberry S; Ghosh J; Hogg KJ; Murphy J; Allgar V; Cleland JGF; Clark AL
ESC Heart Fail; 2019 Dec; 6(6):1149-1160. PubMed ID: 31389157
[TBL] [Abstract][Full Text] [Related]
11. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial.
Simon ST; Kloke M; Alt-Epping B; Gärtner J; Hellmich M; Hein R; Piel M; Cornely OA; Nauck F; Voltz R
J Pain Symptom Manage; 2016 Nov; 52(5):617-625. PubMed ID: 27693898
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
Nicholson B; Ross E; Sasaki J; Weil A
Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
[TBL] [Abstract][Full Text] [Related]
13. Controlled-Release Oxycodone vs. Placebo in the Treatment of Chronic Breathlessness-A Multisite Randomized Placebo Controlled Trial.
Ferreira DH; Louw S; McCloud P; Fazekas B; McDonald CF; Agar MR; Clark K; McCaffrey N; Ekström M; Currow DC;
J Pain Symptom Manage; 2020 Mar; 59(3):581-589. PubMed ID: 31655189
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.
Verberkt CA; van den Beuken-van Everdingen MHJ; Schols JMGA; Hameleers N; Wouters EFM; Janssen DJA
JAMA Intern Med; 2020 Oct; 180(10):1306-1314. PubMed ID: 32804188
[TBL] [Abstract][Full Text] [Related]
15. Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial.
Ekström M; Ferreira D; Chang S; Louw S; Johnson MJ; Eckert DJ; Fazekas B; Clark KJ; Agar MR; Currow DC;
JAMA; 2022 Nov; 328(20):2022-2032. PubMed ID: 36413230
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.
Sima L; Fang WX; Wu XM; Li F
J Clin Pharm Ther; 2012 Feb; 37(1):27-31. PubMed ID: 21208247
[TBL] [Abstract][Full Text] [Related]
17. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study.
Currow DC; McDonald C; Oaten S; Kenny B; Allcroft P; Frith P; Briffa M; Johnson MJ; Abernethy AP
J Pain Symptom Manage; 2011 Sep; 42(3):388-99. PubMed ID: 21458217
[TBL] [Abstract][Full Text] [Related]
18. Opioids for chronic refractory breathlessness: patient predictors of beneficial response.
Johnson MJ; Bland JM; Oxberry SG; Abernethy AP; Currow DC
Eur Respir J; 2013 Sep; 42(3):758-66. PubMed ID: 23258776
[TBL] [Abstract][Full Text] [Related]
19. Chronic breathlessness in advanced cardiorespiratory disease: patient perceptions of opioid use.
Moran T; Zentner D; Wong J; Philip J; Smallwood N
BMJ Support Palliat Care; 2023 Dec; 13(e2):e334-e343. PubMed ID: 33837113
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
